Vaccination and Immunization

Standout updates include a relaxed recommendation for patients with a history of egg allergies, and that all available influenza vaccines for the 2023 to 2024 flu season are quadrivalent.

Bivalent COVID-19 vaccines by both Moderna and Pfizer-BioNTech are no longer authorized for use in the United States.

The effects of GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in patients aged 9 to 15 years has indicated efficacy, according to a recent long-term follow-up study.

According to a recent Morbidity and Mortality Weekly Report, the original COVID-19 monovalent and bivalent vaccines helped reduce emergency department or urgent care encounters for children aged 6 months to 5 years.

Basis for a Biologics License Application submission to the FDA is being built for PXVX0317, following topline results demonstrated in a pair of phase 3 trials, including 1 trial featuring adolescents and adults aged 12 to 64 years.

From vaccinations to classroom behavior to math and reading levels, a discussion on how to best prepare children for the coming academic year.

An analysis of a nationwide sample of more than 30,000 clinicians provides insight into rates of HPV vaccination among US adolescents and how changes in reimbursement rate might encourage increased vaccination rates.

The vaccine efficacy of the Novavax’s NVX-CoV2373 was 79.5% in adolescents.

According to Pfizer, the company’s pneumococcal conjugate vaccine Prevnar 20 has been approved by the FDA to treat infants and children aged 6 weeks to 17 years for the prevention of invasive pneumococcal disease (IPD).

This study surveyed parents’ opinions on the risks of COVID-19 infection versus vaccination to determine how they affected the decision to vaccinate a child against COVID-19.

The COVID-19 pandemic took a massive toll on routine vaccinations for children across the globe. Now, the United Nations Children’s Fund is calling for quick and swift action to get back on track. 

Monovalent vaccines by these manufacturers are no longer authorized for use in the United States.

The FDA recently approved Hyqvia, expanding its use to treat pediatric patients with primary immunodeficiency (PI) aged 2 to 16 years.

In a recent study, vaccination administered during pregnancy was effective against severe lower respiratory tract illness associated with respiratory syncytial virus (RSV) in infants.

A multi-country survey revealed 50% of meningitis vaccination appointments were delayed or canceled amid the COVID-19 pandemic, highlighting the need for “urgent action” to maintain routine vaccination levels among children, according to survey authors.

In a recent review, children with vaccination against human papillomavirus (HPV) initialized at a younger age were more likely to receive their full vaccination series.

If approved by the FDA, this 5-in-1 investigational candidate could provide the broadest meningococcal serogroup coverage.

At the 44th National Association of Pediatric Nurse Practitioners Conference, the CDC provided an updated immunization schedule, detailing new changes.

In a recent study, children aged 5 to 11 years were less likely to be hospitalized with the Omicron strand if they received vaccination against COVID-19.

In a recent report from the CDC, monovalent vaccines from Moderna and Pfizer have shown vaccine effectiveness in children aged 3 to 5 years in at least the first 4 months after vaccination.

A booster dose of mRNA COVID-19 vaccination during pregnancy increases protection of infants from infection and related hospitalization.

A recent study shows that nearly 250,000 children of kindergarten age have not gotten their recommended vaccines. What can pediatric health care providers do to advocate for more vaccine compliance?

The 2023 changes include vaccines for influenza, pneumococcal disease, measles, mumps, and rubella (MMR) and COVID-19.

The Food and Drug Administration (FDA) has approved another Tdap vaccine option for use during pregnancy to prevent pertussis, otherwise known as whooping cough.

The Centers for Disease Control and Prevention has provided an updated safety profile on the bivalent COVID-19 booster vaccine in children aged 5 to 11 years, showing similar adverse events to the monovalent vaccine.